Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Shares of clinical-stage immunotherapy company, Enlivex Therapeutics Ltd. (ENLV) are surging nearly 70% Thursday morning after the company reported positive top-line results from the study of its Covid-19 drug candidate, Allocetra.


RTTNews | Oct 1, 2020 10:14AM EDT

10:14 Thursday, October 1, 2020 (RTTNews.com) - Shares of clinical-stage immunotherapy company, Enlivex Therapeutics Ltd. (ENLV) are surging nearly 70% Thursday morning after the company reported positive top-line results from the study of its Covid-19 drug candidate, Allocetra.

The investigator-initiated study of Allocetra included five Covid-19 patients- three in severe condition and two in critical condition. All five patients had complete recovery from their respective condition and were released from the hospital, following administration of Allocetra, Enlivex said

There were no reported severe adverse events relating to the administration of Allocetra in the patients, and the therapy was well-tolerated, the company noted.

The company plans to start phase IIb study of Allocetra in the fourth quarter of 2020.

Enlivex stock is currently trading at $10.07. It has traded in the range of $3.59- $27.28 in the last one year.

Read the original article on RTTNews ( https://www.rttnews.com/3133153/stock-alert-enlivex-soars-on-positive-results-from-its-covid-19-drug.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC